| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.009 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.09 | 0.01 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.01 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |